Clinical Trial Update: A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CellCept (mycophenolate mofetil) in combination therapy for heart transplant patients has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Heart Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2014-10-29